News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update
Conference Call and Webcast Today, February 20 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Feb. 20, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 18, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 13, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 3, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 21, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 2, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 9, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 3, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 26, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other
View HTML
TOP